ProQR Q2: Runway Extended, But Execution Still Unproven

What happened

ProQR reported second-quarter 2026 results on August 13, with financials showing continued net losses and cash consumption consistent with its development-stage status. The June 2026 financing, which raised $59.2 million gross and included Eli Lilly's $9.2 million participation, extended the cash runway into mid-2028, but also diluted shareholders by roughly 31% from the year-end 2025 share count. The company reiterated its pipeline priorities: AX-0810 follow-up data expected by year-end 2026, AX-0811 entering the clinic, and the China biliary-atresia investigator-initiated trial (IIT) awaiting authorization or site initiation. No new clinical data were disclosed, leaving the investment case dependent on upcoming catalysts rather than current results. The stock remains in a WAIT zone, with the market pricing in more than what filings fully support.

Implication

The Q2 report does not change the risk-reward setup: PRQR trades at $1.70, near the WAIT rating's mid-point, with no margin of safety. Cash runway into mid-2028 provides time, but the company must convert healthy-volunteer biomarker data into patient-path credibility or face further dilution. The next major catalyst is the year-end AX-0810 follow-up data; if it weakens, the thesis breaks and the stock could fall toward $1.05. Conversely, if AX-0810 data hold and the China IIT gains traction, the stock could move toward $2.45. Until those events, we see better entry opportunities below $1.45 or after clear execution evidence.

Thesis delta

No material thesis shift from Q2 results. The investment case remains unchanged: funded exposure to RNA editing validation, but execution risk dominates. Maintain WAIT rating and $1.85 base case implied value.